{"entity":{"id":"ab-1015","kind":"drug","name":"AB-1015","aka":[],"tldr":"AB-1015 is an experimental autologous Integrated Circuit T cell therapy from Arsenal Biosciences, in phase 1 trials for platinum-resistant high-grade serous ovarian, fallopian tube and primary peritoneal cancer; its current status is not stated.","summary":"AB-1015 is an autologous Integrated Circuit T (ICT) cell therapy from Arsenal Biosciences. An autologous Integrated Circuit T cell therapy tested in platinum-resistant ovarian cancer; the sources reached do not name its targets. Its furthest stage is phase 1, for platinum-resistant high-grade serous ovarian, fallopian tube and primary peritoneal cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT05617755 terminated; registry reason: 'Active patients have been rolled over to a separate LTFU study.' Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Arsenal Biosciences: arsenalbio.com","url":"https://arsenalbio.com/2024/04/30/arsenal-biosciences-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-ab-2100-in-development-as-a-treatment-for-clear-cell-renal-cell-carcinoma/"},{"label":"Arsenal Biosciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05617755"},{"label":"ClinicalTrials.gov: trials of AB-1015","url":"https://clinicaltrials.gov/search?intr=AB-1015"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["arsenal-bio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05617755"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AB-1015","modality":"Autologous Integrated Circuit T (ICT) cell therapy","mechanism":"An autologous Integrated Circuit T cell therapy tested in platinum-resistant ovarian cancer; the sources reached do not name its targets.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ab-1015/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/"}],"trial":[{"id":"nct05617755","kind":"trial","name":"AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer","route":"/trials/nct05617755/"}]}}